Jorien Van Der Schaft

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.

Journal: Acta dermato-venereologica

Published: August 16, 2021

Dermpath & Clinic: Pemphigus herpetiformis with vacuolar interface dermatitis and autoantibodies against desmoglein 1 and 3.

Dermpath & Clinic: Pemphigus herpetiformis with vacuolar interface dermatitis and autoantibodies against desmoglein 1 and 3.

Journal: European journal of dermatology : EJD

Published: July 26, 2021

Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis.

Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis.

Journal: The journal of allergy and clinical immunology. In practice

Published: June 24, 2020

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.

Journal: Journal of the American Academy of Dermatology

Published: April 04, 2020

Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.

Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.

Journal: Allergy

Published: February 10, 2020

Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers.

Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers.

Journal: The Journal of allergy and clinical immunology

Published: January 10, 2020

Dupilumab facial redness: Positive effect of itraconazole.

Dupilumab facial redness: Positive effect of itraconazole.

Journal: JAAD case reports

Published: November 05, 2019

Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment.

Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: July 19, 2019

Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?

Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?

Journal: Current opinion in allergy and clinical immunology

Published: May 31, 2019

Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.

Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.

Journal: Allergy

Published: May 25, 2019

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment.

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment.

Journal: Acta dermato-venereologica

Published: May 11, 2019

Towards personalized treatment in atopic dermatitis.

Towards personalized treatment in atopic dermatitis.

Journal: Expert opinion on biological therapy

Published: February 16, 2019

Showing 1-12 of 23

Last Updated: 09/26/2026